Amphastar Pharma (AMPH) Tops Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Amphastar Pharmaceuticals (AMPH) PT Raised to $23 at BMO Capital
March 13, 2019 6:36 AM EDTBMO Capital analyst Gary Nachman raised the price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $23.00 (from $21.00) while maintaining a Market Perform rating.
4Q18 results were good overall, although the quarter did benefit from a couple of one-timers (Enoxaparin and insulin API).Management... More